Printer Friendly

Articles from M2 Pharma (June 20, 2018)

1-29 out of 29 article(s)
Title Author Type Words
Abbvie's Venetoclax in Combination with Rituximab from Phase 3 MURANO Trial Shows High Undetectable Minimal Residual Disease. Clinical report 209
Achieve Life Sciences Inc concludes USD13.8m public offering of units. 208
argenx reports interim data from first cohort of Phase 2 proof-of-concept efgartigimod trial. 228
CollPlant adds new Scientific Advisory Board member. 214
Compugen Engages in Registered Direct Offering for Proceeds of USD 21m. 227
CryoLife Inc names Marna Borgstrom to board. 137
CVS Health Adds Safe Drug Disposal Units in Virginia. 239
Eidos Therapeutics prices initial public offering of 6,250,000 shares of common stock. 173
Eidos Therapeutics prices IPO at USD17.00 per share. 157
Galmed Pharmaceuticals Ltd prices public offering at USD15.00 per ordinary share. 179
Genedrive awarded grant to develop test to avoid antibiotic-related hearing loss in babies. 224
Grifols wins new US FDA approval for the Procleix Ultrio Elite and Procleix WNV assays. 275
Idorsia initiates Phase 3 PRECISION study. 206
iTeos Therapeutics raises USD75m in financing round. 171
Jeffrey Modell Foundation announces grant of USD3.7m in aid of global primary immunodeficiency research. 253
Kindred Biosciences to issue common stock in public offering. 146
Medisafe collaborates with Boehringer Ingelheim Pharmaceuticals. 113
Medisafe signs support partnership with Boehringer Ingelheim. 196
MEI Pharma Releases Ongoing Study Data on ME-401 at the European Hematology Association Congress. 278
NeuroVive Pharmaceutical offers Leber's Hereditary Optic Neuropathy therapy license to BridgeBio Pharma. 173
New Study of Patients with Low-Risk PE Finds Xarelto Reduces Hospital Time, Decreases Costs. 243
Novartis passes US FDA approval of Cosentyx for inclusion of new evidence in slowing down joint structural damage in psoriatic arthritis. 266
Phase II Trial of Aivita's Patient-specific Ovarian Cancer Vaccine Begins with First Patient. Clinical report 234
Results Presented at 2018 EHA Meeting from Advanced Hodgkin Lymphoma Study. Clinical report 284
Spectra Medical Devices awarded US FDA approval to market single use 1% lidocaine ampule. 159
Study Finds JAK Inhibitors and Pre-Existing B Cell Associated with Aggressive Lymphoma. 278
Study Results Reviewed at 2018 EHA Finds Increased Overall Survival Benefit to Obinutuzumab Combined with Chlorambucil in CLL Patients. 288
Trovagene Completes First Dosing Cohort of Patients in Ongoing Phase 1b/2 AML Trial. 274
US Food and Drug Administration grants fast track designation to ImmunoGen's mirvetuximab soravtansine. 217

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters